NREP
NEW REPRESENTATIVE AT IB RECEIVED
30/05/2025
Voltar para busca
Dado oficial do USPTO
VOZRIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
18
Atualização mais recente
31/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
08/01/2021
Data de registro
09/11/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/11/2021
Última transação
31/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
CIANCI, RYAN
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Glaxo Group Limited
Representantes
Legal Brand Protection, GSK
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditionshuman immunodeficiency virus (hiv)human papilloma virusrespiratory syncytial virushepatitisherpes genitalisherpes labialisherpes simplex virusvaricella-zoster virusepstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disordersimmunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disordersautoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditionshuman immunodeficiency virus (hiv)hpvrsvhepatitisherpes genitalisherpes labialisherpes simplex virusvaricella-zoster virusepstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disordersdisorders of the endocrine systemgrowth and thyroid disordersdiabetesmetabolic syndromeobesityweight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascularcardiopulmonarycardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disordersarthritisrheumatoid arthritisinflammatory bowel diseasesinflammatory connective tissue diseasesvasculitissynovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatmentnausea and vomitinghematologic depressionmucositiscachexiapainbone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disordersthrombocytopeniacoagulation disordersbleeding disordersplatelet disordersblood vessel disorderssickle-cell disease and its related disordersanemiassepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseasesdisorders and injuriesconnective tissue diseasesbone diseasesosteoporosisspinal diseasesback paingoutfracturessprainssports injuriesosteogenesis imperfectamuscle wasting (cachexia)renal osteodystrophycartilage injuriesjoint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disordersdermatitisskin and skin structure infectionsbacterial skin infectionsfungal skin infectionsviral skin infections and parasitic skin infectionspsoriasiseczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disordershypogonadismtestosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disordersirritable bowel disorders and symptomsdigestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunctionerectile dysfunctionmale and female sexual dysfunction disordersarousal disorderpain disorderdesire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseasesurological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disordersamenorrhoeadysmenorrheal and infertility; pharmaceutical hormonal preparationscorticosteroidshormone replacement therapy preparationsoral contraceptivesthyroid hormone preparations; pharmaceutical preparations for the treatment of incontinenceprostate diseases and disordersbladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseasesinflammatory pelvic diseasesvasomotor/menopausal symptomsendometriosis/uterine fibroidsleiomyomaendourology/stonepre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitisnephritiscystitisvaginitisrenal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorderpremenstrual syndromemale hypogonadism and hormonal disorderspolycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseaseshepatitisnon-alcoholic fatty liver disease (nafld)non-alcoholic steatohepatitis (nash)liver fibroidscirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disordersmood disordersanxiety disorderscognitive disordersschizophreniapsychoses; pharmaceutical preparations for the treatment of damaged skin and tissuebee stingssunburnrashessorescornscalluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines
Publicações
Histórico de despachos e eventos da marca no USPTO.
18 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
30/07/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/03/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/02/2022
FIMP
FINAL DISPOSITION PROCESSED
22/02/2022
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
09/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
09/11/2021
PUBO
PUBLISHED FOR OPPOSITION
24/08/2021
GPNX
NOTIFICATION PROCESSED BY IB
22/08/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/08/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/08/2021
NPUB
NOTICE OF PUBLICATION
04/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/07/2021
DOCK
ASSIGNED TO EXAMINER
19/07/2021
MAFR
APPLICATION FILING RECEIPT MAILED
19/03/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/03/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
12/03/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/03/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VOZRIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.